Advertisement
News
Advertisement

Biogen begins ALS treatment trial, pays $10M to Knopp

Thu, 03/31/2011 - 10:37am
Mass High Tech: The Journal of New England Technology

Biogen Idec (Nasdaq: BIIB) and its partner Knopp Biosciences have launched a Phase 3 trial for their potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In connection with the launch, Biogen will pay a $10 million milestone payment to Knopp.

If successful, researchers said the experimental drug could be a significant step forward in the treatment of the neurogenerative disease because there is only one currently approved therapy, and it extends patients’ lives for only two or three months.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading